Clinical Trial Detail

NCT ID NCT03734029
Title Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications

breast cancer

Therapies

Trastuzumab deruxtecan

Nab-paclitaxel

Capecitabine

Paclitaxel

Gemcitabine

Eribulin

Age Groups: senior adult

Additional content available in CKB BOOST